Browse Studies — Arctuva

Phase 1

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in co…

Advanced Solid TumorsGenital Neoplasm, FemaleUrogenital Neoplasms+11 more

Estimated

~$10 – $8,750

Marengo Therapeutics, Inc.NCT05592626

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Background: Tumors in the genitourinary tracts can occur in the kidney, bladder, prostate, and testicles and can have common and rare histologies. Some cancer…

Urothelial CancerBladder CancerGenitourinary Cancer+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT04923178

Phase 1

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostat…

Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more

Estimated

~$10 – $8,750

Blue Earth Therapeutics LtdNCT05413850

Phase 4

Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome

This a single-center, prospective, exploratory study. Patients with metastatic castration-resistant prostate cancer (mCRPC) scheduled to undergo Lutetium label…

Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantMetastatic Prostate Cancer+8 more

Estimated

~$10 – $7,500

VA Greater Los Angeles Healthcare SystemNCT06706921